Home / Market Research / Direct to Consumer Microbiome Analyzing Market By Product (Gut Microbiome Test Kits, Other Microbiome Testing Kits & Health Sample Kits), By Application (Infections, Gut Conditions, Metabolic Disorders, Cardiovascular Disease, Others) - Growth, Future Prospects and Competitive Landscape, 2019 – 2027

Direct to Consumer Microbiome Analyzing Market By Product (Gut Microbiome Test Kits, Other Microbiome Testing Kits & Health Sample Kits), By Application (Infections, Gut Conditions, Metabolic Disorders, Cardiovascular Disease, Others) - Growth, Future Prospects and Competitive Landscape, 2019 – 2027


Published: Jun 2019

"Direct to consumer microbiome analyzing market to exhibit dynamic growth during the forecast period" 

The global direct to consumer microbiome analyzing market is growing efficiently, expected to grow at a CAGR of 11.8%. Globally, growing prevalence of chronic diseases along with gut infections has significantly increased the revenue of microbiome testing kits. New product launches along with raised funding for genome testing, and promising pipeline microbiome analyzing products in the DNA testing industry are factors driving the overall growth of direct to consumer microbiome analyzing market globally. 

"Gut microbiome test kits segment is expected to register higher growth by the end of 2027" 

Advancement in diagnostic testing along with sequencing-based clinical microbiome analyzing will enhance the future growth. Direct to consumer DNA testing is expanding significantly, has the capability to detect specific infections, lifestyle diseases, and gut conditions including irritable bowel syndrome and inflammatory bowel disease. For e.g. SmartGut (uBiome, Inc.), it is the world’s first sequencing-based clinical microbiome test. The global giants are investing for further R&D and are encouraging the commercialization of these sample kits in partnerships with smaller organizations to meet the active demand in future. 

"Expansion of services at home for gut microbiome testing to witness a significant CAGR" 

Increasing popularity of DNA testing kits along with services provided at home on a global level are notable factors expected for the growth of the market. Citizen scientists around the world are learning about their microbiomes. These kits are useful for various disease indications and applications including diarrhea, irritable bowel syndrome, inflammatory bowel disease, Crohn’s disease and ulcerative colitis, obesity, type 2 diabetes, chronic kidney disease, cardiovascular disease and many others. The genetics industry is now familiar with the consumer interest in microbiome testing as an opportunity, and a number of top commercial laboratories are marketing these test kits directly on a global level, mainly in the U.S. and Europe market. 

"Increasing population, new FDA approval and the presence of top players holds the U.S. in dominant position" 

In 2018, North America generated maximum revenue share in the direct to consumer microbiome analyzing market due to an increase in expansion of test kits along with raising awareness about new technology with improved outcomes at low cost. Rising home care services along with enhanced reimbursement structure will drive the growth in the near future. For e.g. In Dec 2017, direct-to-consumer DNA and microbiome test were launched in Europe. Atlas Biomed expanded its consumer-oriented DNA and gut microbiome tests with combined analysis on the corporation’s health program. Nevertheless, huge pipeline products, less awareness, accuracy along with data security and FDA regulations are factors restraining the overall growth of the market. 

"Increased research and development with strong product pipelines in the developed regions" 

Major players in the direct to consumer microbiome analyzing market are uBiome, Inc., Viome, Inc., Atlas Biomed and others. Major top organizations and DNA testing and research centers are developing smart technologies with integrated systems. Acquisitions, partnerships and enhanced R&D will improvise the expansion of direct to consumer microbiome analyzing market in the developing nations in near future. 

Historical & Forecast Period 

This study report represents analysis for each segment from 2017 to 2027 considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027

Market Segmentation 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 Product Type (2017–2027; US$ Mn)
 • Gut Microbiome Test Kits
 • Other Microbiome Testing Kits & Health Sample Kits

 Application Segment (2017–2027; US$ Mn)
 • Infections
 • Gut Conditions
 • Metabolic Disorders
 • Cardiovascular Disease
 • Others

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (Japan, China, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East & Africa (GCC, Rest of Middle East & Africa)

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints and opportunities that gives a better market understanding of the overall direct to consumer microbiome analyzing market. Additionally, the global report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.

Key questions answered in this report 

  • What are the current market trends and dynamics in the direct to consumer microbiome analyzing market and valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which product type segment holds a larger market share and why?
  • Are low and middle-income economies investing in the direct to consumer microbiome analyzing market?
  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America and Middle East & Africa?

TABLE 1 Market Snapshot: Global Direct To Consumer Microbiome Analyzing (DCMA) Market
TABLE 2 Global DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 3 Global DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 4 Global DCMA Market, by Geography, 2017–2027 (US$ Mn)
TABLE 5 North America DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 6 North America DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 7 North America DCMA Market, by Country, 2017–2027 (US$ Mn)
TABLE 8 Europe DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 9 Europe DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 10 Europe DCMA Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 11 Latin America DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 12 Latin America DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 13 Latin America DCMA Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 14 Asia Pacific DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 15 Asia Pacific DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 16 Asia Pacific DCMA Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 17 Middle East & Africa DCMA Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 18 Middle East & Africa DCMA Market, by Application, 2017–2027 (US$ Mn)
TABLE 19 Middle East & Africa DCMA Market, by Region, 2017–2027 (US$ Mn)
TABLE 20 uBiome, Inc..: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 Viome, Inc..: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 Quantbiome, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 7.3. Atlas Biomed: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 7.5. FINCH THERAPEUTICS: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 7.6. MaaT Pharma: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 7.7. Kallyope Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +